ASCO 2018 Highlight (Conference Call)

from the beginning

ASCO 2018 Highlight

Forward-looking Statements

• Today's Agenda

1.DS-8201

ADC | DS-8201: mature FTIH phase 1 results, n=241 across HER2 tumors

ADC | DS-8201: Tumor Shrinkage by Tumor Types: (5.4 or 6.4 mg/kg)

ADC | DS-8201: Tumor Shrinkage Over Time by Tumor Type: (5.4 or 6.4 mg/kg)

ADC | DS-8201: Activity in Breast Cancer HER2-low (by standard IHC)

ADC | DS-8201: Activity in HER2 Tumors:

ADC | DS-8201: Efficacy Outcomes by Tumor Type (5.4 or 6.4 mg/kg)

ADC | DS-8201: Overall Safety Profile (5.4 or 6.4 mg/kg) N=241

ADC | DS-8201: AE of Special Interest (5.4 or 6.4 mg/kg) n=241

Breast Cancer Treatment Landscape 2018*

Breast Cancer Treatment Landscape 2018*

Breast Cancer Treatment Landscape 2018*

ADC | DS-8201: Broad & Bold Development Program

ADC | DS-8201 (trastuzumab deruxtecan) Top News

2.U3-1402

ADC | U3-1402: A Novel, Anti-HER3 Antibody

U3-1402 & DS-8201: In vitro Intracellular Disposition

U3-1402 & DS-8201: ADC-trafficking to Lysosome

ADC | U3-1402: Study Design

ADC | U3-1402: Treatment-Emergent AE in > 15%

ADC | U3-1402: Treatment-Emergent AE in > 15%

ADC | U3-1402: Activity

Daichi Sankyo ADC DXd Technology:

Daichi Sankyo ADC DXd Technology:

ADC | Franchise Focus and Flagship Asset

3.Pexidartinib

Pexidartinib | ENLIVEN placebo-controlled phase 3 study Background

Pexidartinib | ENLIVEN Primary Endpoint: Tumor Response by RECIST

Pexidartinib | ENLIVEN Clinical Benefit Endpoints

Pexidartinib | ENLIVEN Hepatotoxicity

Pexidartinib: Hepatotoxicity Outside of TGCT

4.Quizartinib

Quizartinib Single Agent in AML

5.Cancer Enterprise

ADC Franchise

Breakthrough and AML Therapies Moving to Market

CE Major Clinical Pipeline

Cancer Enterprise | 2025 Vision

Cancer Enterprise | 2018 FOCUS

A ForceToday, A LeaderTomorrow

Contact address regarding this material

Q&A

• Q&A 1

• Q&A 2

• Q&A 3

• Q&A 4

• Q&A 5